10008316 - Rechallenge Conversion/Auger-Electron plus Beta-minus Particle Therapy with Terbium-161 labeled Somatostatin Receptor Antagonist DOTA-LM3 in Neuroendocrine Tumors – Convalescence Phase I/II Study
Research Project | 01.05.2026 - 30.04.2030
|
01.05.2026
- 30.04.2030
Funding
10008316 - Rechallenge Conversion/Auger-Electron plus Beta-minus Particle Therapy with Terbium-161 labeled Somatostatin Receptor Antagonist DOTA-LM3 in Neuroendocrine Tumors – Convalescence Phase I/II Study
SNF Projekt (GrantsTool), 05.2026-04.2030 (48)
PI : Wild, Damian.
Members (1)
